On the stock market since 2014, it operates in the world of health and science. It has 316 employees. Now — the numbers.
The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.
An average decline of 20% a year over the last 4 years — the most striking risk in this picture. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
Executives buying with their own money is usually read as confidence in the company’s future.
angles, checked one by one.
The 5 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Profit per Sale: Right now the product sells for less than it costs to make; every sale deepens the loss.
The stock trades near its peak today. For long-term holders the ride has paid off so far — though past performance guarantees nothing about the future.
The company sells $7.5M a year; the problem isn’t sales — it’s costs running above that number.
There is $548.9M in the vault; even if every debt were paid off, $540.9M would remain.
Over the last 12 months, company executives reported 63 buys and 46 sells. Management buying with its own money is usually read as a good sign.
A loss of $345.9M against $7.5M in annual sales.
At the current pace of spending, the cash lasts about 1.6 years. After that, the company needs to find new money.
On our five-subject report card, XENE sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: XENE is a small company that closed last year at a loss. The road back to profit runs through spending discipline.